Evidence map›Paper›PMID 36838665›Full record

ArticleMolecules (Basel, Switzerland)2023

Exploring the Chemical Space of CYP17A1 Inhibitors Using Cheminformatics and Machine Learning.

Tianshi Yu, Tianyang Huang, Leiye Yu, Chanin Nantasenamat, Nuttapat Anuwongcharoen, Theeraphon Piacham, Ruobing Ren, Ying-Chih Chiang

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Extremely Randomized Trees to Determine Binding Affinity.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Tianshi YuKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen 518172, China.
Tianyang HuangKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen 518172, China.
Leiye YuShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200438, China.
Chanin NantasenamatStreamlit Open Source, Snowflake Inc., San Mateo, CA 94402, USA.ORCID 0000-0003-1040-663X
Nuttapat AnuwongcharoenCenter of Data Mining and Biomedical informatics, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.ORCID 0000-0001-5361-5314
Theeraphon PiachamDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.ORCID 0000-0001-8975-9520
Ruobing RenShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200438, China.ORCID 0000-0003-4517-7216
Ying-Chih ChiangKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen 518172, China.ORCID 0000-0002-1585-7213
Mahidol University · THChinese University of Hong Kong, Shenzhen · CNFudan University · CNSnowflake Inc. (United States)

Funding

This research was funded by Science, Technology and Innovation Commission of Shenzhen Municipality JCYJ-20180508163206306
6 · The paper itself

Abstract

Cytochrome P450 17A1 (CYP17A1) is one of the key enzymes in steroidogenesis that produces dehydroepiandrosterone (DHEA) from cholesterol. Abnormal DHEA production may lead to the progression of severe diseases, such as prostatic and breast cancers. Thus, CYP17A1 is a druggable target for anti-cancer molecule development. In this study, cheminformatic analyses and quantitative structure-activity relationship (QSAR) modeling were applied on a set of 962 CYP17A1 inhibitors (i.e., consisting of 279 steroidal and 683 nonsteroidal inhibitors) compiled from the ChEMBL database. For steroidal inhibitors, a QSAR classification model built using the PubChem fingerprint along with the extra trees algorithm achieved the best performance, reflected by the accuracy values of 0.933, 0.818, and 0.833 for the training, cross-validation, and test sets, respectively. For nonsteroidal inhibitors, a systematic cheminformatic analysis was applied for exploring the chemical space, Murcko scaffolds, and structure-activity relationships (SARs) for visualizing distributions, patterns, and representative scaffolds for drug discoveries. Furthermore, seven total QSAR classification models were established based on the nonsteroidal scaffolds, and two activity cliff (AC) generators were identified. The best performing model out of these seven was model VIII, which is built upon the PubChem fingerprint along with the random forest algorithm. It achieved a robust accuracy across the training set, the cross-validation set, and the test set, i.e., 0.96, 0.92, and 0.913, respectively. It is anticipated that the results presented herein would be instrumental for further CYP17A1 inhibitor drug discovery efforts.

Indexed as

CheminformaticsEnzyme InhibitorsSteroid 17-alpha-HydroxylaseDehydroepiandrosteroneMachine LearningQuantitative Structure-Activity RelationshipSteroidsDehydroepiandrosteroneEnzyme InhibitorsSteroid 17-alpha-HydroxylaseSteroidscheminformaticsCYP17A1Murcko scaffoldprostate cancerquantitative structure–activity relationship

Identifiers

PMID36838665
PMCPMC9966999
OpenAlexW4319924597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.